Former Head of Roche Diagnostics, North America, Has 25 Years of Life Sciences Industry Experience
RANCHO CORDOVA, Calif., Aug. 6 /PRNewswire-FirstCall/ -- ThermoGenesis
Corp. (Nasdaq: KOOL), a leading supplier of innovative products that process
and store adult stem cells, said today that Tiffany P. Olson, formerly
President and Chief Executive Officer, Roche Diagnostics Corporation, North
America, has been named to the Company's Board of Directors. Her appointment
brings the Company's number of directors to six.
Olson, who has more than 25 years of healthcare industry experience, led
the over one billion dollar operation for Roche Diagnostics Corporation for
three years. Roche Diagnostics is a world-leader in in-vitro diagnostics and
specializes in products and services for the molecular, chemistry, immunology,
point-of care and life sciences markets. She joined Roche in 1997 and her
positions also included Global Market Development and Quality, Vice President,
Molecular Diagnostics, United States and other senior positions.
'Tiffany's appointment is emblematic of our initiative to elevate both the
Board of Directors and management team at ThermoGenesis. Her extensive
experience in key areas of the healthcare industry will provide us invaluable
insight as we pursue our growth strategies in that market,' said Dr. William
Osgood, Chief Executive Officer of ThermoGenesis.
'This is an exciting time to be associated with ThermoGenesis. It is
building upon its already strong position in regenerative medicine through
developments such as the recent FDA authorization of its MarrowXpress(TM) and
I look forward to working with the management team,' Olson commented.
Olson holds a B.S. in Business from the University of Minnesota School of
Management and an MBA from the University of St. Thomas in St. Paul,
Minnesota.
About ThermoGenesis Corp.
ThermoGenesis Corp. (www.thermogenesis.com) is a leader in developing and
manufacturing automated blood processing systems and disposable products that
enable the manufacture, preservation and delivery of cell and tissue therapy
products. These products include:
-- The BioArchive(R) System, an automated cryogenic device, is used by
cord blood stem cell banks in more than 25 countries for cryopreserving and
archiving cord blood stem cell units for transplant.
-- AXP(TM) AutoXpress Platform (AXP(TM)) is a proprietary family of
automated devices that includes the AXP and the MarrowXpress(TM) and companion
sterile blood processing disposable for harvesting stem cells in a closed
system. The AXP device is used for the processing of cord blood. GE
Healthcare is the exclusive global distribution partner for the AXP cord blood
product except for Central and South America, China and Russia/CIS, where
ThermoGenesis markets through independent distributors. The MarrowXpress is
used for isolating stem cells from bone marrow. ThermoGenesis sells the
MarrowXpress directly to global customers.
-- The CryoSeal(R) FS System, an automated device and companion sterile
blood processing disposable, is used to prepare fibrin sealants from plasma in
about an hour. The CryoSeal FS System is approved in the U.S. for liver
resection surgeries. The CryoSeal FS System has received the CE-Mark which
allows sales of the product throughout the European community. Asahi Medical
is the exclusive distributor for the CryoSeal System in Japan and the Company
markets through independent distributors in Europe and South America.
-- The Thrombin Processing Device(TM) (TPD(TM)) is a sterile blood
processing disposable that prepares activated thrombin from a small aliquot of
plasma in less than 30 minutes. The CE-Marked TPD is currently being marketed
in Europe by Biomet, Inc., subsidiary Biomet Biologics, Medtronic, Inc. and
independent distributors.
This press release contains forward-looking statements, and such
statements are made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. These statements involve risks and
uncertainties that could cause actual outcomes to differ materially from those
contemplated by the forward-looking statements. Several factors, including
timing of FDA approvals, changes in customer forecasts, our failure to meet
customers' purchase order and quality requirements, supply shortages,
production delays, changes in the markets for customers' products,
introduction timing and acceptance of our new products scheduled for fiscal
year 2009, and introduction of competitive products and other factors beyond
our control, could result in a materially different revenue outcome and/or in
our failure to achieve the revenue levels we expect for fiscal 2009. A more
complete description of these and other risks that could cause actual events
to differ from the outcomes predicted by our forward-looking statements is set
forth under the caption 'Risk Factors' in our annual report on Form 10-K and
other reports we file with the Securities and Exchange Commission from time to
time, and you should consider each of those factors when evaluating the
forward-looking statements.
ThermoGenesis Corp.
Web site: http://www.thermogenesis.com
Contact: Investor Relations
916-858-5107, or
ir@thermogenesis.com
SOURCE ThermoGenesis Corp.
